Background Cancer patients have been reported to be at higher risk of COVID-19 complications
and deaths. We report the characteristics and outcome of patients diagnosed with …

Nowadays, the mechanisms governing the occurrence of cancer are thought to be the
consequence not only of genetic defects but also of epigenetic modifications. Therefore, …

Background Concerns have emerged about the higher risk of fatal coronavirus disease 2019
(COVID-19) in cancer patients. In this article, we review the experience of a comprehensive …

Background Thymic malignancies represent a heterogeneous group of rare thoracic cancers,
which are classified according to the World Health Organization histopathologic …

Background High throughput molecular screening techniques allow the identification of multiple
molecular alterations, some of which are actionable and can be targeted by molecularly …

Introduction Sequential anti–programmed cell death protein 1 (PD-1) or anti–programmed
death-ligand 1 (PD-L1) followed by small targeted therapy use is associated with increased …

Background Stage IIIA/B-N2 is a very heterogeneous group of patients and accounts for one
third of NSCLC at diagnosis. The best treatment strategy is established at a Multidisciplinary …

Thymic tumours are rare thoracic malignancies, that may be aggressive and difficult to treat.
The pillars of the management include pathological review, consideration of differential …

Introduction Thymic epithelial tumors (TETs) are rare intrathoracic malignancies for which
surgery represents the mainstay of the treatment. Current practice for postoperative …

Contexte. The Epidermal Growth Factor Receptor (EGFR) is mutated in 10–15% of patients
with lung adenocarcinoma. At metastatic stage EGFR tyrosine kinase inhibitors (TKIs) are …